BERYL DRUGS LIMITED
Regd. Off.: 29, Neer Nagar, "Mayank Water Park Road", Bicholi Hapsi, **INDORE**-452016 (M.P.) INDIA
Tel. : (0731) 2517677 | **E-mail :** beryldrugs25@yahoo.com | **CIN :** L02423MP1993PLC007840

Date: 14.11.2026

To,

The Secretary,
Department of Corporate Services,
Bombay Stock Exchange Limited (BSE),
Phiroze Jeejeebhoy Towers, Dalal Street,
Mumbai – 400001

Scrip Code: 524606

Sub.: Disclosure of Regulation 30 read with Part- A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sirs,

Pursuant to Regulation 30 read with Part- A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board of Directors in its 6/2026-2027 Board Meeting held on 14.11.2026 has approved the Unaudited Financial Results of the Company for the Quarter ended 30.09.2026.

We hereby request you to kindly acknowledge the receipts of same.

Thanking You,

Yours Sincerely

For Beryl Drugs Limited

BERYL DRUGS LTD. Director

Sudhir Sethi
Chairman& Director
DIN: 00090172

BERYL DRUGS LIMITED
29, Neer Nagar, Mayank Water Park Road, Bicholi Hapsi, Indore (M.P.)-452016
Tel./ Fax 0731-2517677
E-mail : beryldrugs25@yahoo.com

ANNEXURE I

Submission of Unaudited Financial Result by Companies Other than Banks

Part I

(Rs in lacs)

Statement of standalone Unaudited Result for the Quarter/half year ended 30/09/2026

Particulars	Quarter ended			Half year ended		Year ended
	3 months ended (30-09-2026)	Preceding 3 months ended (30-06-2026)	Corresponding 3 months ended in the previous year (30-09-2025)	Year to date figures for current period ended (30-09-2026)	Year to date figures for previous period ended (30-09-2025)	Previous year ended (31-03-2026)
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Income						
(a) Revenue From Operations						
Net sales or Revenue from Operations	693.28	729.67	512.00	1422.95	991.43	1882.01
Other Income	13.88	26.96	3.66	40.84	7.81	49.00
Total Income	**707.16**	**756.63**	**515.66**	**1463.79**	**999.24**	**1931.02**
2 Expenses						
(a) Cost of materials consumed	416.21	433.99	278.90	850.20	499.77	1050.99
(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
(c) Changes in Inventories of Finished Goods and Work-in-Progress	-30.70	8.99	-20.76	-21.71	-39.10	-74.32
(d) Employee benefit expense	89.08	63.13	57.68	152.21	111.07	252.88
(e) Finance costs	4.90	6.20	8.02	11.10	18.11	34.43
(f) Depreciation and amortisation expense	23.20	31.60	39.15	54.80	77.23	149.32
(g) Other Expenses	194.75	185.74	126.64	380.49	299.16	458.92
Total expenses	**697.44**	**729.65**	**489.63**	**1427.09**	**966.24**	**1872.22**
3 Profit before tax (1-2)	**9.72**	**26.98**	**26.03**	**36.70**	**33.00**	**58.80**
4 Tax Expense						
Current tax	4.48	1.32	10.66	5.80	25.66	10.69
Mat Tax Credit	-2.21	0.00	0.00	-2.21	0.00	0.00
Adjustments in respect of current income tax of prior years	0.37	0.00	0.68	0.37	0.68	0.69
Deferred tax	1.41	3.58	13.80	4.99	3.66	4.94
Total Tax Expenses	**4.05**	**4.90**	**25.14**	**8.95**	**30.00**	**16.32**
5 Profit after tax (3- 4)	**5.67**	**22.08**	**0.89**	**27.75**	**3.00**	**42.48**
Other comprehensive income	-0.23	0.68	-0.24	0.45	0.00	-1.81
6 Total Comprehensive Income	**5.44**	**22.76**	**0.65**	**28.20**	**3.00**	**40.68**
7 Details of equity share capital						
Paid-up equity share capital	507.17	507.17	507.17	507.17	507.17	507.17
Face value of equity share capital	10.00	10.00	10.00	10.00	10.00	10.00
8 Earnings per share						
(a) Basic earnings per share before extraordinary items	0.11	0.44	0.02	0.55	0.06	0.84
(b) Diluted earnings per share before extraordinary items	0.11	0.44	0.02	0.55	0.06	0.84

Notes:

1. The above financial results have been prepared in accordance with the recognition and measurement principles stated therein prescribed under Section 133 of the
2. The above results for the quarter ended 30th September 2026 which have been subjected to Limited Review by Statutory Auditors of the Company were reviewed and
3. The Income from Operations is from one segment namely "Pharmaceutical Industry".
4. The figures for the previous periods have been regrouped, wherever necessary.
5. Depreciation is provided on Written down value method on the estimated remaining useful lives of the assets.
6. The Company has considered internal and external information upto the date of approval of these financial results in assessing the recoverability of financial and non
7. Earnings per Share amount is Shown in Rupees.
8. The above results were taken on record at the meeting of the board of director held on November 14th, 2026.

For and on behalf of the Board of Directors
For Beryl Drugs Limited

Sanjay Sethi
Managing Director
DIN : 00090277

Date: 14/11/2026
Place:Indore

BERYL DRUGS LIMITED
29, Neer Nagar, Mayank Water Park Road, Bicholi Hapsi, Indore (M.P.)-452016
CIN: L02423MP1993PLC007840

UNAUDITED STATEMENT OF ASSETS AND LIABILITIES AS AT 30th SEPTEMBER 2026

(Rs. In Lacs)

PARTICULARS	As At 30/09/2026 (Unaudited)	As At 30/09/2025 (Unaudited)	As At 31/03/2026 (Audited)
ASSETS			
Non-Current Assets			
Property Plant and Equipment	597.26	739.75	654.44
Right of Use Assets	40.11	0.00	27.75
Capital Work-in-Progress	0.00	82.72	0.00
Investment Property	23.24	22.18	21.73
Intangible Assets	0.07	0.07	0.07
Financial Assets			
Investments	0.00	0.00	0.00
Trade Receivables	0.00	0.00	0.00
Loans	0.00	0.00	0.00
Other Financial Assets	126.72	33.14	19.59
Deferred Tax Assets (Net)	0.00	0.00	0.00
Other Non-Current Assets	154.48	46.49	89.75
Total Non-Current Assets	**941.88**	**924.35**	**813.33**
Current Assets			
Inventories	309.75	276.30	312.64
Financial Assets			
Investments	0.00	0.00	0.00
Trade Receivables	324.15	421.93	208.83
Cash and cash equivalents	33.52	6.68	27.35
Bank Balance other than above	0.00	0.00	0.00
Loans	0.00	0.00	0.00
Other Financial Assets	13.05	6.21	19.78
Current Tax Asset (Net)	0.00	0.00	0.00
Other Current Assets	104.29	105.66	114.40
Assets held for Sale			
Total Current Assets	**784.76**	**816.78**	**683.00**
Total Assets	**1726.64**	**1741.13**	**1496.33**
EQUITY AND LIABILITIES			
Equity			
Equity Share capital	509.37	509.37	509.37
Other Equity	507.59	437.48	479.38
Total Equity	**1016.96**	**946.85**	**988.75**
Liabilities			
Non-Current Liabilities			
Financial Liabilities			
Borrowings	0.00	156.71	0.00
Lease Liability	13.47	0.00	4.90
Provisions	52.17	52.30	50.92
Deferred Tax Liabilities (Net)	8.84	0.75	3.69
Other Non-Current Liabilities	0.00	0.00	0.00
Total Non-Current Liabilities	**74.48**	**209.76**	**59.51**
Current Liabilities			
Financial Liabilities			
Borrowings	235.63	273.42	239.13
Lease Liability	4.38	0.00	0.05
Trade payables			
: total outstanding dues of micro enterprises and small enterpri	10.12	21.21	9.03
: total outstanding dues of creditors other than micro enterprises and small enterprises	300.33	164.47	133.55
Other Financial Liabilities	16.22	38.81	18.85
Other Current Liabilities	46.42	47.28	24.61
Provisions	18.09	14.86	15.46
Current Tax Liabilities (Net)	4.01	24.47	7.39
Total Current Liabilities	**635.20**	**584.52**	**448.07**
Total Liabilities	709.68	794.28	507.58
Total Equity and Liabilities	**1726.64**	**1741.13**	**1496.33**

For and on Behalf of the Board of Directors
For Beryl Drugs Limited

SANJAY SETHI
(MANAGING DIRECTOR)
DIN:00090277

Date: 14/11/2026
Place:Indore

Beryl Drugs Limited

CIN : L02423MP1993PLC007840

Registered Office : 29, Neer Nagar, Mayank Water Park Road, Bicholi Hapsi, Indore (M.P.)-452016

Statement of Cash Flow for the Six Month ended on 30th Septmber 2026

(Rs. In lacs)

S. No.	Particulars	For the six month 30-09-26 Unaudited	For the six month 30-09-25 Unaudited	For the year ended 31-03-26 Audited
A	**Cash Flow from Operating Activities**			
1	**Profit Before Tax**	36.70	33.00	58.80
	Add : Depreciation, Amortization and Impairment	54.80	77.23	149.32
	Add : Finance Cost	11.10	18.11	34.43
	Less : Rental Income	-10.28	-6.68	-13.37
	Less : Dividened Received	0.00	0.00	0.00
	Less : Acturial gain of PVBDO	0.00	0.00	0.00
	Less : Loss on sales of fixed Assets	0.43	0.00	0.00
	Less : Capital Gain on Sale of Shares	0.00	0.00	0.00
2	**Operating Profit Before Working Capital Changes**	92.75	121.66	229.18
3	**Adjustment for :**			
	(Increase) / Decrease in Operating Assets			
	Inventories	2.88	-86.02	-122.36
	Trade Receivables	-115.32	123.78	336.88
	Other Financial Assets	-100.39	-2.59	4.05
	Other Non Current Assets	-64.73	0.43	-42.83
	Other Current Assets	10.10	-31.50	-47.68
	Increase/(Decrease) in Operating Liabilities and Provisions			
	Provisions	3.89	2.89	9.91
	Trade Payables	167.88	74.13	31.03
	Other Financial Liabilities	-2.63	16.18	-3.78
	Other Current Liabilities	21.81	9.21	-13.46
4	**Cash Flow used in Operations**	16.24	228.17	380.94
	Payment of Income Tax	-7.50	-12.46	-16.00
	Net Cash Used in Operating Activities (A)	8.74	215.71	364.94
B	**Cash Flow from Investing Activities**			
1	Purchase of Property Plant and Equipments (PPE)	-53.86	-301.82	-382.42
2	Construction of godown held as Investment Property	-1.51		-2.91
2	Proceeds from Government Grant in respect of tangible assets	44.21		155.62
3	Proceeds from Sales of Tangible Assets	0.00	0.00	0.00
4	Capital Advances and Others	0.00	0.00	0.00
5	Proceeds from Sales of Investments	0.00	0.00	0.00
6	Rental Income	10.28	6.68	13.37
7	Bank Balances other than Cash & Cash Equivalents	0.00	0.00	0.00
8	Payment of Liabilities Held for Sale	0.00	0.00	0.00
9	Dividend Income	0.00	0.00	0.00
	Net Cash Used in Investing Activities (B)	-0.88	-295.14	-216.34
C	**Cash Flow from Financing Activities**			
1	Repayment of lease liabilities	12.91		-0.05
2	Changes in Short Term Borrowings	-3.51	39.65	36.89
3	Proceeds from Long Term Borrowings	0.00	0.00	0.00
4	Repayment of Long Term Borrowings	0.00	-16.87	-205.10
5	Finance Costs	-11.10	-18.11	-34.43
6	Loans Given	0.00	0.00	0.00
7	Receipt of Loan Given	0.00	0.00	0.00
	Net Cash Used in Financing Activities (C)	-1.70	4.67	-202.69
	Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)	6.16	-74.76	-54.08
	Cash and Cash Equivalents at the Beginning of the Year	27.35	81.44	81.44
	Cash and Cash Equivalents at the End of the Year	33.51	6.68	27.35
	Components of Cash and Cash Equivalents:			
	Cash on Hand	13.25	6.06	5.98
	Balance with bank in Current Account	20.26	0.62	21.38
	Fixed Deposit having maturity less than 3 months	0.00	0.00	0.00
		33.51	6.68	27.35

For and on behalf of the Board of Directors

BERYL DRUGS LTD. Director

Sanjay Sethi
Managing Director
DIN : 00090277

Date: 14/11/2026
Place:Indore

Subhash Chand Jain Anurag & Associates

Chartered Accountants
104, Archana Apartment, 8-B, Ratlam Kothi,Indore-452001 (MP)
PH # 2519439, 2527682 FAX # 0731 2519116
Mob. No. : +91-9302123882
Email: scjainca2004@yahoo.com

Independent Auditor's Review Report on Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,
The Board of Directors
Beryl Drugs Limited

1. We have reviewed the accompanying statement of unaudited financial results of **Beryl Drugs Limited** ("the Company") for the quarter ended September 30, 2026 and the year to date result for the period from April 01, 2026 to September 30, 2026 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended (the "Listing Regulations').

2. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors and prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under section 133 of the Companies Act, 2013 read with rule 3 of Companies (Indian Accounting Standard) rules 2015, as amended read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410,"Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consist of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain

assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33, Regulation52 and Regulation 54 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

ForSubhash Chand Jain Anurag & Associates
Chartered Accounts
FRN: 004733C

SUBHASH CHAND JAIN ANURAG & ASSOCIATES
FRN 004733C INDORE
Chartered Accountants

(Akshay Jain)
Partner
M.No.447487
UDIN: 26447487VBXUTM5619

Date : 14/11/2026
Place: Indore